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In recent years, mesenchymal cell-based products have been developed to improve
surgical therapies aimed at repairing human tissues. In this context, the tooth has
recently emerged as a valuable source of stem/progenitor cells for regenerating orofacial
tissues, with easy access to pulp tissue and high differentiation potential of dental pulp
mesenchymal cells. International guidelines now recommend the use of standardized
procedures for cell isolation, storage and expansion in culture to ensure optimal
reproducibility, efficacy and safety when cells are used for clinical application. However,
most dental pulp cell-based medicinal products manufacturing procedures may not be
fully satisfactory since they could alter the cells biological properties and the quality of
derived products. Cell isolation, enrichment and cryopreservation procedures combined
to long-term expansion in culture media containing xeno- and allogeneic components are
known to affect cell phenotype, viability, proliferation and differentiation capacities. This
article focuses on current manufacturing strategies of dental pulp cell-based medicinal
products and proposes a new protocol to improve efficiency, reproducibility and safety
of these strategies.
Keywords: human dental pulp, stem cells, tissue engineering, immunophenotyping, expansion, cryopreservation,
good manufacturing practices, cell-based medicinal products
Introduction
Over the two last decades, mesenchymal stromal cells (MSC) have been intensely studied due
to their potential clinical applicability to treat tissue and organ defects resulting from diseases,
trauma or aging (Caplan, 1991). Their use has been proposed to repair and regenerate human
mesenchymal tissues, alone or combined to scaffolds and/or morphogenic molecules (Langer
and Vacanti, 1993). Bone marrow and adipose tissue are conventional sources of MSC, but
invasive cell collection protocols, frequent use of general anesthesia and risk of morbidity at the
collection site have stimulated the search for alternative tissues (Huang et al., 2009; Zuk, 2010;
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Davies et al., 2015). Third molars are frequently removed for
therapeutic reasons and the connective tissue it contains, the
dental pulp, can be easily recovered. They are now considered
a valuable source of MSC for tissue repair and regeneration
(Mayo et al., 2014). In this context, numerous investigators have
attempted to obtain clinical-grade dental pulp stem/progenitor
cells (DPSC) from these teeth. However, most manufacturing
procedures reported so far may not be totally satisfactory, since
theymay alter the biological properties of the cells and the quality
of the derived cell-based products (Ménard and Tarte, 2013).
If such procedures are currently permitted by European and
American regulation authorities, further studies are necessary
to develop more efficient, reproducible, safe and standardized
manufacturing processes of dental pulp cell-based medicinal
products (Tirino and Papaccio, 2012; Albuquerque et al., 2014;
Eubanks et al., 2014; Huang and Garcia-Godoy, 2014; La Noce
et al., 2014; Nakashima and Iohara, 2014).
Dental pulp mesenchymal cells have been successfully used
to regenerate human craniofacial bone (d’Aquino et al., 2009;
Giuliani et al., 2013). However, these studies were performed
in the absence of defined, universally accepted protocols for
large-scale, clinical-grade production of DPSC (Fekete et al.,
2012). This point is important in the light of recent reports
indicating moderate, irreproducible and non-suitable benefits
of therapies performed with various sources of MSC (Allison,
2009; Tyndall, 2011; Daley, 2012). These results were explained
in part by the fact that cell performances are affected by
cell isolation and expansion conditions and indicate the need
for optimized and standardized procedures for MSC-based
products’ manufacturing (Allison, 2009; Pacini, 2014). The
European Union (EU) and United States (US) have established
classifications and recommended guidelines for manufacturing
MSC-based products. In Europe,MSC are defined as “cell therapy
products” and referred to as Advanced Therapy Medicinal
Products (ATMP) (European Regulation 1394/2007). ATMP
are considered Cell-Based Medicinal Products (CBMP) when
containing living cells or tissues. CBMP are “medicinal products
presented as having properties for, or used in or administered to,
human beings with a view to treating, preventing or diagnosing
a disease in which the pharmacological, immunological or
metabolic actions are carried out by cells or tissues” (Schneider
et al., 2010; Pacini, 2014). DPSC belong to this category and can
be referred to as Dental Pulp (DP)-CBMP. In the US, DPSC are
considered as Human Cells, Tissues or cellular and tissue-based
Products (HCT/Ps) (Code of Federal Regulation (CFR) Title 21
CFR 1271). They are classified in two categories: (1) products that
are “minimally manipulated” and used clinically in a homologous
manner, and (2) products that are either “more than minimally
manipulated” or used in a non-homologous manner. A cell-
based product is considered as being “more than minimally
manipulated” when the inherent biological characteristics of the
cells have been significantly altered (Pacini, 2014).
Production and delivery of MSCs should be made in
accordance with European Good Manufacturing Practices
(GMP), whereas, in the US, it must comply with Current Good
Tissue Practice requirements (GTP) (Fekete et al., 2012; Kellathur
and Lou, 2012; Sensebé et al., 2013). GMP/GTP require many
quality controls regarding donor eligibility, sample recovery,
label, transport and receipt, process and storage, laboratory
equipment, supplies and reagents, cell-based product distribution
to recipient patients and documentation that must be maintained
by the handler (Alici and Blomberg, 2010; Abou-El-Enein
et al., 2013; Sensebé et al., 2013; Wuchter et al., 2015). These
controlsmakeGMP/GTP procedures long and costly, and further
studies are encouraged to develop shorter, less expensive and
more standardized procedures for DP-CBMP manufacturing
(Albuquerque et al., 2014; Eubanks et al., 2014; Huang and
Garcia-Godoy, 2014; La Noce et al., 2014; Nakashima and
Iohara, 2014; Hilkens et al., 2015). In the present paper, we will
firstly review current international guidelines regarding the five
manufacturing steps of DP-CBMP (Figure 1), and then we will
highlight the drawbacks and potential risks of actual strategies.
Finally we will propose modifications of the protocols intended
to increase the efficiency, reproducibility and safety of these
strategies, from tooth extraction to the harvest of clinical-grade
DP-CMBP.
Teeth Collection and Pulp Tissue Recovery
Since the discovery of DPSC by Gronthos et al. (2000), numerous
papers have reported the isolation of stem/progenitor cells from
the dental pulp of human third molars. However, since there are
no rules specifying the best tooth development stages for pulp
cell collection, teeth were collected in patients of various ages and
therefore at various developmental stages. It also greatly impairs
the interpretation and comparison of the experimental results.
Transport from the operating block to the laboratory notably
requires a medium that does not affect cell viability. It was
previously shown that DPSC remain viable up for 5 days when
extracted teeth are maintained in phosphate-buffered saline
(PBS) (Perry et al., 2008;Woods et al., 2009) and this time is more
than enough for the transport of samples to the laboratory and
pulp recovery.
Dental Pulp Cell Isolation and Enrichment
After dental pulp recovery, two options are possible for isolating
dental pulp cells: enzymatic dissociation and explant culture.
Enzymatic dissociation consists of digesting the pulp tissue with
collagenase and dispase enzymes to liberate the cells that are
then plated on culture dishes. However, a growing number of
authors consider that enzymatic dissociation is not adapted to
medicinal manufacturing, owing to its putative consequences
on cell phenotype and properties (Shah et al., 2013; Busser
et al., 2014; Ohnuma et al., 2014). In addition, tissues and cells
exposed to collagenase are considered “more than minimally
manipulated” by FDA [Code of Federal Regulation (CFR) Title
21 CFR 1271] and potentially require the use of pharmaceutical
grade manufactured enzymes, which significantly increases the
scale-up costs. By contrast, cell isolation by explant culture
increasingly appears easier, faster, safer, less expensive and more
in line with GMP guidelines to obtain clinical-grade amounts
of MSC (Hilkens et al., 2013). It is based on the growth
of cells out of tissue fragments (explants) that are plated on
culture dishes. It recently allowed for efficient recovery of human
adipose or Wharton jelly stem/progenitor cells in serum-free,
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FIGURE 1 | Standardization of the DP-CBMP manufacturing
process. It requires five major steps: tooth selection and use of the
easiest technique for pulp recovery (Step 1), HDPC isolation with fast,
safe and less expensive procedures (Step 2), cell expansion in defined,
serum-free culture conditions with xeno-free reagents (Step 3), advanced
monitoring and control of DP-CBMP manufacturing (Step 4), use of
clinical-grade DP-CMBP, for immediate implantation, cryobanking or
development of a bioassay (Step 5).
xeno-free medium conditions (Busser et al., 2014; Swamynathan
et al., 2014). Additionally, explant-derived DPSC display similar
or enhanced differentiation abilities compared with cells from
dissociated tissue (Spath et al., 2010; Hilkens et al., 2013).
Cell selection by sorting methods has been proposed to
enrich the cultured cell population in stem/progenitor cells based
on their expression of specific surface markers such as CD34,
CD184, Stro-1, CD146, CD271, and MSCA-1 (Shi and Gronthos,
2003; d’Aquino et al., 2009; Waddington et al., 2009; Yu et al.,
2010; Jiang et al., 2012; Tomlinson et al., 2015). However, the
use of such a procedure is today limited by the complexity of the
technique and the prohibitive cost (Kawashima, 2012; Nakashima
and Iohara, 2014). Besides, multiplying steps and using additional
reagents increase the risk of microbial contamination and
the difficulty to obtain CBMP in GMP conditions. The same
reservation can bemade regarding the use of biophysical markers
that have been found relevant to isolate MSC in an easier and
more predictable way than biochemical markers (Lee et al., 2014).
Dental Pulp Cell Culture and Expansion
Among other factors, the composition of the culture medium
and the presence of a coating material on the culture dish
may influence the nature and the quality of the final CBMP
and therefore the clinical results (Lopez-Cazaux et al., 2006;
Majd et al., 2009; Jung et al., 2012; Pisciotta et al., 2012;
Pacini, 2014). Currently, CBMP manufacturing under GMP
procedures recommends the use of xeno-free materials and
reagents to prevent the risk of viral, bacterial, fungal and prion
contamination, and the possible induction of immunizing effects
in the final recipient. Additionally, industrial production is
responsible for frequent batch-to-batch serum variability and
the serum itself can promote early cell differentiation (Mannello
and Tonti, 2007; Jung et al., 2012). For these reasons, the
supplementation of the cell culture medium with xeno- or
allogeneic products should be limited to “cases for which a valid
alternative cannot be found” (European Regulation 1394/2007).
Today, the development of xeno-free, serum-free, defined media,
able to rapidly expand stem/progenitor cells without impairing
their differentiation capabilities, represents a major objective for
the standardization of DP-CBMP production (Tekkatte et al.,
2011; Jung et al., 2012; Bonnamain et al., 2013; Carvalho et al.,
2013). Multiple passages are often necessary to obtain a clinical-
scale amount of cells, but they may lead to a slow-down of
the proliferation rate, progressive cell senescence and loss of
multipotentiality that prevent future cell differentiation (Baxter
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et al., 2004; Bork et al., 2010; Yu et al., 2010; Sensebé et al.,
2013). In our culture conditions, cell doubling times remained
constant from P1 to P4 (≈40 h) and we calculated that more than
25.107 cells could be theoretically obtained after four passages
with one dental pulp, which is likely to be a sufficient cell number
for one pulp regeneration, bone socket filling, or for localized
periodontal treatment (Kaigler et al., 2013; Albuquerque et al.,
2014).
DP-CBMP Manufacturing Control
DP-CBMP manufacturing requires advanced quality controls
of the safety, identity and efficacy of the final product (Wang
et al., 2005; Sensebé et al., 2013). Since CBMP cannot undergo
sterilization before implantation, the absence of bacteria, virus,
fungi and prion contamination has to be checked. The presence
of endotoxin must also be tested to prevent immune reactions
in the recipient patient. Long-term ex vivo expansion of cells
increases the risk of genetic instability and the occurrence of
potential chromosomal abnormalities, since there exists a close
relation between cell senescence and risk of transformation
(Baxter et al., 2004; Rubio et al., 2005; Campisi, 2007). To
limit this risk, the number of population doublings should be
kept to a minimum. In addition, conventional karyotyping must
be combined with fluorescence in situ hybridization (FISH) or
comparative genomic hybridization (CGH array) to assess the
genomic stability of scaled-up cell populations (Barkholt et al.,
2013).
The control of the population identity into expanding cell
cultures is generally realized by flow cytometry analysis of surface
antigens. During the past decade, most of these controls have
been realized in compliance with the recommendations of the
International Society of Cellular Therapy (ISCT) (Dominici et al.,
2006). However, it is today acknowledged that several markers
initially proposed by ISCT for the positive characterization of
MSC (for instance CD73, CD90, and CD105) are shared by
several populations of cells including progenitor cells, mature
fibroblasts or perivascular cells (Russell et al., 2010; Alt et al.,
2011; Halfon et al., 2011; Al-Nbaheen et al., 2013; Lv et al.,
2014).
DP-CBMP Uses
Over recent years, DP-CBMP were clinically tested with the
aim to regenerate human craniofacial bone. DP-CBMP were
implanted, in association with a collagen I-based sponge scaffold,
in mandibular bone sockets in a phase I clinical trial (d’Aquino
et al., 2009). Three years after DP-CBMP grafting, the tissue
regenerated in the graft site was compact bone (Giuliani et al.,
2013). Case reports of osteoradionecrosis treatment using DP-
CBMP were also reported (Manimaran et al., 2014). The
angiogenic, neurogenic and odontogenic potential of DP-CBMP
was also successfully tested in preclinical studies (Gandia et al.,
2008; Iohara et al., 2009; Sakai et al., 2012; Ishizaka et al., 2013).
In addition, a phase I clinical trial is currently under progress to
evaluate the DP-CBMP potential to regenerate the human dental
pulp (Nakashima and Iohara, 2014). Despite these successes,
potential applicability of DP-CBMP will be closely dependent on
their final production cost and their large-scale clinical outcomes.
In particular, a high cost-efficacy ratio would constitute a serious
impediment for their routine use. Hence, it is necessary to have
a clear overview and understanding of the complete value chain
to try to reduce costs (Abou-El-Enein et al., 2013, 2014; Leijten
et al., 2015).
Storage of cryopreserved cell-based products (cryobanking)
over long periods of time offers unique opportunities to
increase DP-CBMP applicability. However, similar to cell culture
and expansion, cryopreservation is associated with infective,
prion, toxicological and immunological risks owing to the
presence of human or animal components and additives such
as DMSO in the storage medium (Papaccio et al., 2006;
Perry et al., 2008; Woods et al., 2009; Lee et al., 2012).
Accordingly, xeno-free, defined cryopreservation media must be
privileged.
DP-CBMP could also be used in biomedical research as
components of bioassay kits to investigate the effects of drugs
on dental pulp cells in a reproducible “humanized” system
(Jurga et al., 2010; Leeb et al., 2011; Forraz et al., 2013). Such
kits are reliable preclinical alternatives to animal models in the
actual regulatory context. Assessment of the risks related to
chemical products’ use and screening or testing new therapeutic
molecules are indeed extremely complicated and costly. The
average costs to take a blockbuster drug to clinical trials are
estimated to be around 1 billion euros. Furthermore, the accuracy
of toxicological and preclinical studies greatly depends on
the experimental animal models used for such evaluations. In
particular, rodent species, widely use, are known to only partially
mimic the human biological system. Development of DP-CBMP
bioassay kits would offer a prime platform to successfully induce
dentinogenesis, osteogenesis or neurogenesis in vitro (Zhang
et al., 2006;Woloszyk et al., 2014; Jensen et al., 2015; Leijten et al.,
2015).
Proposals for a Protocol with a More GMP
Compliant Approach (Figure 2)
We recently proposed the use of impacted third molars between
Nolla’s developmental stages 5 (crown almost completed) and 7
(one third root completed). The presence of large, open apices in
teeth without roots or with roots partially developed allows for an
easy access to the pulp tissue and its gentle, atraumatic extirpation
from the enamel/dentin shell with fine tweezers. It avoids the
cell stress resulting from the crown-root mechanical separation
with a drill or a clamp that is necessary for recovering pulps
from teeth with more developed or complete roots (Perry et al.,
2008; Takeda et al., 2008; Ducret et al., in press). Additionally,
human dental pulp cells (HDPC) isolated at around the crown-
completed stage displayed short cell doubling times and high
growth rate (Takeda et al., 2008). We found similar results in
our study. We also selected impacted teeth to minimize the risk
of pulp tissue contamination and disease transmission by oral
microorganisms (Nolla, 1960; Ducret et al., in press). This choice
may enable to skip the step of sample disinfection performed
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FIGURE 2 | Important steps during DP-CBMP manufacturing that require modification. Major drawbacks, risks and pitfalls are highlighted for each one, and
proposals are made for the development of more GMP-compliant procedures.
with chemicals such as chlorhexidine or povidone-iodine/sodium
thiosulfate (Perry et al., 2008; d’Aquino et al., 2009). When using
PBS as a transportmedium, we failed to detect any contamination
in cultures of HDPC (n > 50 patients) during the isolation and
expansion steps, contrary to others (Perry et al., 2008; Ducret
et al., in press). This might be related to our selection of impacted
teeth from young patients (13–17 year-old) that have never
been in contact with the septic oral cavity, versus the selection
of erupted ones from older patients (18–30 year-old) by those
authors.
Regarding cell isolation, we used explant culture for
recovering human dental pulp cells for clinical application. Each
pulp sample was cut into about 20 explants that allowed for the
harvest of a total of one million dental pulp cells after 14 days of
culture (Ducret et al., in press). This result is in agreement with
other studies reporting that, whatever the technique used (tissue
dissociation or explant culture), 2 weeks of culture allow for the
recovery of about 106 cells from one third molar pulp (Eubanks
et al., 2014).
We pre-coated the culture dish surface for cell isolation and
culture with an equal mixture of human placental collagens I and
III. This composition was chosen because they are the two most
abundant collagens in the dental pulp extracellular matrix. Xeno-
free dissociating reagents (such as TrypLe R© or Accutase R©) and
xeno-free defined culture medium (such as SPE-IV R© [ABCell-
Bio, France], containing clinical grade human albumin, α-MEM,
rhIGF-1 and rhFGF-2) are recommended for cell culture and
passaging instead of the products commonly used (Carvalho
et al., 2013; Ducret et al., in press). Moreover, cryopreservation of
dental pulp cells in serum-free medium had no negative impact
on cell doubling times and cumulative cell numbers (Ducret et al.,
in press). Although the viability of cells cryopreserved in serum-
free medium was decreased compared to fresh cells, it is similar
to that previously reported (Lee et al., 2012).
Future investigations are required for identifying more
specific membrane markers for these cells. In our study,
immunophenotypic analysis of 17 surface markers revealed
that our dental pulp cell expanding population was made
of mesenchymal cells, a percentage of whom expressed the
mesenchymal stem cell/progenitor markers CD146 and MSCA-
1. The number of cells expressing these markers remained similar
from P1 to P4, suggesting that the cell fate was not significantly
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affected by our culture conditions. In addition, cell karyotyping
by G-band analysis showed that this rapid expansion did not lead
to genomic instability that would be potentially harmful for the
recipient patient (Ducret et al., in press).
Conclusion and Perspectives
Recent successes in bone and dental pulp regeneration therapies
carry the promise to use dental pulp-cell-based medicinal
products in the near future. However, current strategies to
manufacture DP-CBMP are not totally satisfactory since they
do not comply with current international guidelines. New
manufacturing standardized protocols, intended to increase
efficiency, reproducibility and safety of these strategies, are
urgently needed. Further investigations are also warranted to
estimate the real benefit of DP-CBMP use compared to current
therapeutic options and precisely determine the cost-efficacy
ratio that risks being a major block for the large-scale clinical use
of these cell-based products.
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